Combined treatment of Ewing Sarcoma with BRD- and CDK9-inhibitors resulted in enhanced responses compared to individual drugs not only in vitro but also in a preclinical mouse model in vivo [46]. Here, CDK9 is linked to Ewing sarcoma.